RXC008
Fibrostenotic Crohn's Disease
Phase 2 ReadyActive; FDA Fast Track Designation
Key Facts
Indication
Fibrostenotic Crohn's Disease
Phase
Phase 2 Ready
Status
Active; FDA Fast Track Designation
Company
About Redx Pharma
Redx Pharma is a focused, AIM-listed biotech with a mission to translate innovative science into novel treatments for fibrosis and cancer. The company has achieved key milestones, including Fast Track designation for its lead GI-restricted ROCK inhibitor (RXC008) and reporting Phase 2a data for its systemic ROCK2 inhibitor, zelasudil (RXC007). Its strategy centers on a proprietary drug discovery platform, a balanced pipeline of proprietary and partnered assets, and a clear path to value inflection through clinical data readouts and strategic partnerships.
View full company profile